Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05337137 · ClinicalTrials.gov registry record · Phase 1

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

A Phase 1 study of Carcinoma, Hepatocellular, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
83
Enrollment target
20
Study locations

NCT05337137 is a Phase 1 study of Carcinoma, Hepatocellular that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 83 participants, below the 609-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05337137, a Phase 1 study of Carcinoma, Hepatocellular, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

Conditions Studied

Carcinoma, Hepatocellular

Interventions

  • DRUG Bevacizumab
  • OTHER Placebo
  • DRUG Nivolumab
  • DRUG Relatlimab

Study Locations (20)

California

  • Local Institution - 0042 - Los Angeles
  • Local Institution - 0039 - Los Angeles
  • Local Institution - 0034 - San Francisco

Massachusetts

  • Local Institution - 0060 - Boston
  • Local Institution - 0065 - Boston

New York

  • Local Institution - 0061 - New York
  • Local Institution - 0062 - The Bronx

Victoria

  • Local Institution - 0026 - Heidelberg
  • Local Institution - 0013 - Melbourne

District of Columbia

  • Local Institution - 0030 - Washington D.C.

Maryland

  • Local Institution - 0059 - Baltimore

Wisconsin

  • Local Institution - 0033 - Milwaukee

New South Wales

  • Local Institution - 0045 - Camperdown

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2022-05-05
Est. Completion 2025-11-18
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05337137

The ClinicalTrials.gov registry entry for NCT05337137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (86% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT05337137 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05337137 about?

NCT05337137 is a clinical study titled "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer". The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

What is the current status of trial NCT05337137?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2022-05-05. Estimated completion is 2025-11-18.

What conditions does trial NCT05337137 study?

This clinical trial studies the following conditions: Carcinoma, Hepatocellular.

What interventions are being tested in trial NCT05337137?

The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Nivolumab (DRUG), Relatlimab (DRUG).

Who is sponsoring clinical trial NCT05337137?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05337137 being conducted?

This trial has 20 study locations across California, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Hepatocellular

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Hepatocellular

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.